Bioline RX Ltd Sponsored ADR (BLRX) has released an update. BioLineRx Ltd has announced promising results from a Phase 1 clinical trial ...

By studying tomato varieties that produce fruit in exceptionally hot growing seasons, biologists at Brown University identified the growth cycle phase when tomatoes are most vulnerable to extreme heat ...

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.

Positive clinical data with confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) and prospective ACR-368 OncoSignature patient ...

JinkoSolarAs a frontrunner in the integration of photovoltaic and energy storage technologies, JinkoSolar consistently enhances its technological innovation capabilities, prioritizes R&D investments, ...

Q3 2024 Earnings Call Transcript November 14, 2024 Operator: Good afternoon, ladies and gentlemen, and welcome to the Inovio Third Quarter 2024 Financial Results Conference Call. At this time, all ...

Inovio Pharmaceuticals (NASDAQ: INO) Q3 2024 Earnings Call Nov 14, 2024, 4:30 p.m. ET ...

Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that the first patients have been dosed in an initial trial studying the potential of the company’s CAR-NK cell therapy ...

The topline results showed that Amelus and BF-RhodoLED lamp therapy met primary and secondary endpoints in the Phase III ...

NM32 is a first-in-class half-life-enhanced T-cell engager targeting ROR1, a tumor associated antigen with broad expression in solid tumors and hematological malignancies Low molecular weight of NM32 ...